Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.

Cancer discovery - 1 May 2017

Thomas Daniel, Majeti Ravindra

Abstract excerpt

<b/> AG-221 or enasidenib is a first-in-class selective inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) with early demonstrated clinical efficacy in acute myeloid leukemia as a single agent, yet with persistence of mutant IDH2 clones. Two articles in this issue of Cancer Discovery provide further insight into the biological activity of AG-221 in promoting differentiation of IDH2-mutant cells and reversing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to FLT3 gene
Share to IDH2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 28461409
DOI: 10.1158/2159-8290.CD-17-0270
PMCID: PMC5456121

Genes

IDH2
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.PMID 28461409Read ↗

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.Semantic proximity Read ↗

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in VivoSemantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaSemantic proximity Read ↗

IDH2 inhibition in AML: Finally progress?Semantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

More than just another IDH inhibitor: Insights from the HMPL-306 phase 1 trial.Semantic proximity Read ↗

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.Semantic proximity Read ↗

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersSemantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.